PDCD1 and non-small cell lung carcinoma: ﻿Despite great progress in the development of immune checkpoint inhibitors, particularly the encouraging therapy of PD-L1/PD-1 blockade, a portion of NSCLC patients remain generally resistant to these therapies [42].